依达拉奉与尿激酶静脉溶栓共同治疗急性脑梗死的临床分析  

Clinical Analysis of Edaravone Combined with Urokinase Intravenous Thrombolysis in the Treatment of Acute Cerebral Infarction

作　　者：何重福 施彦[1] 江斌 徐磊[1] HE Chong-fu;SHI Yan;JIANG Bin;XU Lei(Department of Neurology,Xinfeng People’s Hospital,Ganzhou Jiangxi 341600,China)

机构地区：[1]江西省信丰县人民医院神经内科

出　　处：《药品评价》2019年第22期56-57,共2页Drug Evaluation

摘　　要：目的:研究急性脑梗死患者实施依达拉奉与尿激酶静脉溶栓联合治疗的临床效果。方法:选择52例于我院接受急性脑梗死治疗的患者,将其随机分为实验组与参照组,每组均26例。其中参照组采用尿激酶静脉溶栓,实验组行依达拉奉与尿激酶静脉溶栓联合治疗,对比两组患者治疗前后相关评分、临床疗效。结果:治疗后、出院前NIHSS、mRS评分均低于参照组,与参照组相比,实验组急性脑梗死临床疗效(96.15%)高于参照组(69.23%),组间可见显著差异性(P<0.05)。结论:急性脑梗死患者行依达拉奉与尿激酶静脉溶栓联合治疗效果确切,能够改善患者脑部炎性症状及氧化应激反应,有效保护免患者脑部细胞。Objective:To study the clinical effect of edaravone combined with urokinase intravenous thrombolysis in patients with acute cerebral infarction.Methods:Fifty-two patients with acute cerebral infarction treated in our hospital were enrolled and randomly divided into experimental group and reference group by drawing lots,with 26 cases in each group.The control group was treated with urokinase intravenous thrombolysis,and the experimental group was treated with edaravone combined with urokinase intravenous thrombolysis.Relevant scores and clinical efficacy of the two groups were compared before and after treatment.Results:After treatment and before discharge,NIHSS and mRS scores were lower than those of the control group.Compared with the control group,the clinical efficacy of acute cerebral infarction in the experimental group(96.15%)was higher than that in the control group(69.23%).There were significant differences between the two groups(P<0.05).Conclusion:Edaravone combined with urokinase intravenous thrombolysis is effective in treating acute cerebral infarction.It can improve the inflammatory symptoms and oxidative stress reaction of patients with cerebral infarction,and effectively protect brain cells from patients.

关 键 词：急性脑梗死 依达拉奉 尿激酶静脉溶栓 

分 类 号：R743.33[医药卫生—神经病学与精神病学]